A5042335238- Diabetes Treatment and Management
- Pharmaceutical Practices and Patient Outcomes
- Diabetes Management and Research
- Medication Adherence and Compliance
- Heart Failure Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Management and Education
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Chronic Disease Management Strategies
- Blood Pressure and Hypertension Studies
- Metabolism, Diabetes, and Cancer
- Lipoproteins and Cardiovascular Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Pharmacology and Obesity Treatment
- Primary Care and Health Outcomes
- Pneumonia and Respiratory Infections
- Cardiovascular Function and Risk Factors
- Healthcare Systems and Practices
- Emergency and Acute Care Studies
- Cardiac Arrest and Resuscitation
- Health, Medicine and Society
- Pharmaceutical Economics and Policy
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pharmacy and Medical Practices
- Acute Myocardial Infarction Research
University of Alberta
2016-2025
Alliance for Canadian Health Outcomes Research in Diabetes
2013-2024
Ibero American University
2015
Pharmaceutical Biotechnology (Czechia)
2012
St. John's School
2012
Canadian Pharmacists Association
2012
Canadian Institutes of Health Research
2007-2010
University of Alberta Hospital
2009
Health Sciences Centre
2009
Alberta Hospital Edmonton
2009
OBJECTIVE—The aim of this study was to examine the relationship between use metformin and sulfonylurea mortality in new users these agents. RESEARCH DESIGN AND METHODS—Saskatchewan Health databases were used population-based rates for oral antidiabetic Individuals with prescriptions or 1991–1996 no year prior identified as users. Prescription records prospectively followed 1–9 years; subjects any insulin excluded. Causes death based on ICD-9 codes an electronic vital statistics database....
Over the past 30 years, relation between use of sulfonylureas to treat type 2 diabetes and risk cardiovascular events has been vigorously debated. The purpose this study was determine if death changes with level exposure sulfonylurea drugs.This a retrospective, inception cohort using administrative data from Saskatchewan Health (1991-1999). 5795 subjects, identified by their first-ever dispensation for an oral antidiabetic agent, were grouped according such agents during follow-up. Potential...
To compare population-based rates of all-cause and cardiovascular (CV) mortality in newly treated patients with type 2 diabetes according to levels insulin exposure.Using the administrative databases Saskatchewan Health, 12272 new users oral antidiabetic therapy were identified between 1991 1996 grouped cumulative exposure based on total dispensations per year: no (reference group); low (0 <3); moderate (3 <12) high (> or =12). Time-varying multivariable Cox proportional hazards models used...
Abstract Aim Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use relation to risk of cardiovascular‐related hospitalization and mortality. Methods We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases identify new users oral antidiabetic drugs. Subject groups were defined by medication during 1991–1999: sulphonylurea...
OBJECTIVE To evaluate the effect of adding pharmacists to primary care teams on management hypertension and other cardiovascular risk factors in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS We conducted a randomized controlled trial blinded ascertainment outcomes within clinics Edmonton, Canada. Pharmacists performed medication assessments limited history physical examinations provided guideline-concordant recommendations optimize management. Follow-up contact was completed as...
<b>Objective</b> To determine if the use of sitagliptin in newly treated patients with type 2 diabetes is associated any changes clinical outcomes. <b>Design </b>Retrospective population based cohort study. <b>Setting </b>Large national commercially insured US claims and integrated laboratory database. <b>Participants</b> Inception new users oral antidiabetic drugs between 2004 2009 followed until death, termination medical insurance, or December 31 2010. <b>Main outcome measure</b>...
An individual's location of residence may impact health, however, health services and outcomes research generally use a single point in time to define where an individual resides. While this estimate becomes inaccurate when the study subject moves, on observed associations is not known. This quantifies different methods (rural, urban, metropolitan) association with all-cause mortality. A diabetes cohort new metformin users was identified from administrative data Alberta, Canada between 2008...
Background and Purpose— Cardiovascular risk factors are suboptimally treated in diabetes, possibly because of the impression that there is a long delay between diagnosis development macrovascular complications such as stroke. We determined incidence stroke people newly for type 2 diabetes. Methods— conducted an inception cohort study with use linked administrative databases from Saskatchewan Health. Subjects entered diabetes on receipt their first prescription oral antidiabetic drug. defined...
Background: Optimal medication management requires an effective relationship between the patient and health care professional. As pharmacists move from traditional dispensing role to become more actively involved in care, factors influencing their with patients need be identified. A better understanding of these will facilitate relationships. Objective: To explore effect patient-perceived pharmacist expertise on quality, self-efficacy, satisfaction, commitment. Methods: This was a...
Previous outcomes-based studies of adherence to diabetes medications have focused on glycemic control and are limited by questions temporality uncontrolled confounding.This retrospective cohort study new oral antidiabetic medication users examined the effect risk incident macrovascular microvascular complications.A nationwide integrated insurance claims laboratory database was used identify between January 2004 December 2009. People with preexisting complications were excluded remaining...